MA-BATTERY-VENTURES
26.3.2024 12:01:26 CET | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, today announced a significant investment in Mobius Institute (“Mobius”), a company that specializes in reliability improvement, conditioning-monitoring, and precision-maintenance training and certification.
Mobius delivers its training via public, in-plant, and online training programs and has trained more than 70,000 professionals from 180 countries since 2005. In addition to training, a related entity to the company, Mobius Institute Board of Certification, is an ISO/IEC 17024 and ISO 18436-accredited certification body that provides globally recognized certification to reliability professionals, vibration analysts, ultrasound analysts, thermal imaging, and lubrication specialists worldwide.
Mobius Institute is seen as an authority in the industrial asset-reliability space, which is growing in importance as companies transition to predictive and data-based maintenance regimes to operate more efficiently and meet new sustainability targets. Via its network of training partners, Mobius has trained maintenance and reliability professionals across a wide range of industries with students from Pfizer, Rio Tinto, Abbott, Abbvie, Ford, Coca-Cola, Samsung, ABB, Cargill, Nestle, Siemens, Dow, Amazon, Bayer, Mercedes-Benz, NASA, and Hyundai, among others.
Jason Tranter, the co-founder of Mobius, said he hoped the partnership with Battery will help his company scale to a new level. “My wife, Georgie, and I started the business in our house in 1999 with the goal of making vibration analysis and condition monitoring understandable. We never imagined Mobius Institute growing to this scale with almost 10,000 students trained last year alone,” he said. “Having developed a relationship with Battery over the past several years, I am excited to see Mobius continue to grow under Battery’s ownership as the starting point of a new platform.”
As part of the transaction, Tranter will serve as a technical advisor to Mobius.
Battery’s goal with the transaction is to create a large, innovative, asset-reliability and industrial-services player; the firm expects to build upon Mobius’ strength in asset reliability while expanding the portfolio into the broader market for industrial training, certification, and specialized products & services.
As part of this initiative, Marcus Pillion joins the company as Group CEO to drive M&A and continued organic growth, as well as to oversee integration efforts. Pillion joins Mobius after serving most recently as the CEO of Des-Case before its acquisition by Timken (NYSE: TKR) in 2023. Prior to Des-Case, Pillion had previous executive experience across several asset-reliability and condition-monitoring businesses including TRITEC Performance Solutions, Colfax Fluid Handling, EagleBurgmann, SKF and John Crane.
“I am excited to join forces with Battery, a seasoned industrial-technology investor with extensive experience creating platforms through global M&A,” said Pillion. “Having used Mobius Institute training across all of the companies I previously worked for, I am excited to build upon the global brand Mobius has created as we enter into the next phase of its growth trajectory.”
“We are thrilled to partner with Mobius and its exceptional staff as we pursue the next phase of growth for the business,” said Zack Smotherman, a Battery general partner. “Having followed the asset-reliability and condition-monitoring market for many years, we’ve observed an accelerating trend in predictive maintenance and believe we are still in the early innings of this movement as many industries increasingly adopt these solutions.”
Added Battery Principal Justin Rosner: “We are grateful to Jason for the opportunity to partner with Mobius and excited about the journey ahead as we look to leverage Mobius’s global reputation to improve asset reliability across many industries in the years to come.”
About Mobius Institute
Mobius Institute is a worldwide provider of reliability improvement, condition monitoring, and precision maintenance education to industrial plant managers, reliability engineers, and condition monitoring specialists, allowing plants to be successful in implementing reliability improvement and condition monitoring programs. Mobius delivers its training via public, in-person / onsite, and online education programs with a key advantage being its unique training style that uses innovative 3D animations and software simulations, making complex topics easier to understand. Mobius has trained and certified more than 70,000 industrial professionals from 180 countries since 2005 with thousands more engaged through distance learning programs and Mobius’ online community MOBIUS CONNECT. Learn more at https://www.mobiusinstitute.com/about-mobius-institute/.
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326724392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release
A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom